As previously reported, BofA downgraded LianBio to Underperform from Buy with a price target of $3, down from $5, given what the firm sees as lower pipeline optionality and expectations for the pipeline to yield little data throughout 2024. It isn’t clear to the firm what the cash deployment picture looks like to preserve pipeline and portfolio optionality, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LIAN:
- Nanobiotix says LianBio enters NBTXR3 development pact with Johnson & Johnson
- LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
- LianBio downgraded to Hold from Buy at Jefferies
- LianBio announces departure of CFO Larson, Gu appointed interim CFO
- LianBio Announces Departure of Chief Financial Officer
